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Abstract
Introduction
Anemia, syphilis and HIV are high burden diseases among pregnant women in sub-Saharan
Africa. A quasi-experimental study was conducted in four health facilities in Southern
Mozambique to evaluate the effect of point-of-care technologies for hemoglobin quantifica-
tion, syphilis testing and CD4+ T-cell enumeration performed within maternal and child health
services on testing and treatment coverage, and assessing acceptability by health workers.
Methods
Demographic and testing data on women attending first antenatal care services were
extracted from existing records, before (2011; n = 865) and after (2012; n = 808) introduction
of point-of-care testing. Study outcomes per health facility were compared using z-tests
(categorical variables) and Wilcoxon rank-sum test (continuous variables), while inverse
variance weights were used to adjust for possible cluster effects in the pooled analysis. A
structured acceptability-assessment interview was conducted with health workers before (n
= 22) and after (n = 19).
Results
After implementation of point-of-care testing, there was no significant change in uptake of
overall hemoglobin screening (67.9% to 83.0%; p = 0.229), syphilis screening (80.8% to
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87.0%; p = 0.282) and CD4+ T-cell testing (84.9% to 83.5%; p = 0.930). Initiation of antire-
troviral therapy for treatment eligible women was similar in the weighted analysis before and
after, with variability among the sites. Time from HIV diagnosis to treatment initiation
decreased (median of 44 days to 17 days; p<0.0001). A generally good acceptability for
point-of-care testing was seen among health workers.
Conclusions
Point-of-care CD4+ T-cell enumeration resulted in a decreased time to initiation of antiretro-
viral therapy among treatment eligible women, without significant increase in testing cover-
age. Overall hemoglobin and syphilis screening increased. Despite the perception that
point-of-care technologies increase access to health services, the variability in results indi-
cate the potential for detrimental effects in some settings. Local context needs to be consid-
ered and services restructured to accommodate innovative technologies in order to improve
service delivery to expectant mothers.
Introduction
The reduction of maternal and infant mortality is dependent on the effective treatment of key
diseases during antenatal care. The availability of timely laboratory diagnosis has been a long-
standing challenge in resource-limited countries, especially in rural settings where maternal
and child health (MCH) indicators remain poor. The arrival in the last decade of point-of-care
(POC) technologies relevant to MCH services has brought renewed hope for increasing the
coverage, breadth and quality of health care among women and children living in these territo-
ries. For the purpose of this study, POC testing referred to testing that was conducted at or
near the patient, with no requirement for laboratory infrastructure, and that yielded results in a
very short timeframe. These technologies can guide immediate treatment management deci-
sions during the clinic visit [1]. For pregnant women, this may improve management of medi-
cal conditions associated with maternal and child morbidity and mortality. The recent
introduction of POC testing for CD4+ cell counting in health systems [2–4] has stimulated a
fresh debate about the quality and access to comprehensive diagnostics within MCH services.
Anemia is common among pregnant women in sub-Saharan Africa, aggravated by poor
nutritional status, and parasitic infestation with organisms such as malaria and hookworm [5].
Worldwide, prevalence of anemia during pregnancy is estimated at 42% [6]. Congenital syphi-
lis remains a major health problem worldwide and is often neglected [7, 8]. An estimated 1.5
million pregnant women are yearly infected with syphilis [9]. In addition, there is increased
risk of vertical transmission of HIV among women co-infected with syphilis [10]. Screening for
and treatment of syphilis during pregnancy can prevent congenital syphilis and decrease the
risk of stillbirths [11]. In 2013, about 210,000 children in sub-Saharan Africa were newly
infected with HIV, the majority through mother-to-child transmission (MTCT) [12]. Vertical
transmission to infants is largely preventable with the use of antiretroviral medications. At the
time of the study, the World Health Organization (WHO) guidelines recommended combina-
tion antiretroviral therapy (ART) for individuals with CD4+ T cell count less than 350 cells/μl
or WHO stage III-IV, making CD4+ T cell enumeration necessary for eligibility determination.
Providing ART in MCH or ensuring an immediate link fromMCH to HIV services are crucial
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to avoid delays in treatment initiation as ART is a proven and effective MTCT prevention strat-
egy [13].
In Mozambique pregnant women are highly burdened by HIV (15.8% prevalence, 2011
[14]), syphilis (2.2% prevalence, 2011[14]) and anemia (52% prevalence, 2005 [6]). About 90%
of the pregnant women attend antenatal clinics (ANC) at least once but only half attend all
four visits, as recommended by WHO [15]. Comprehensive MCH services require access to
screening and diagnostic assays to identify ailments and allow for timely interventions. Even
when diagnostic tests are physically available within a health facility laboratory, pregnant
women may not access these services if return visits to the facility are required for results and/
or are associated with long waiting times. Since many years, testing for hemoglobin and syphi-
lis for pregnant women have been available at health facilities’ laboratories in Mozambique,
while samples for CD4+ cell enumeration among HIV-infected individuals are collected weekly
and sent to a referral laboratory located within higher level health facilities.
The objectives of this operational research study were to determine: (i) the effect of the
introduction of an integrated package of POC testing services for quantification of hemoglobin
and CD4+ T cells, and syphilis serology within MCH services on coverage of testing; (ii) the
effect of POC testing on initiation and timing of ART among ART-eligible HIV-positive preg-
nant women; and (iii) the acceptability of the use of POC technologies by health professionals.
Methods
Design, population, location
A quasi-experimental operational research study was conducted in four rural public health
facilities in two provinces (Maputo and Gaza) in southern Mozambique. The sites (Moamba,
Macia, Magude and Marracuene) were purposively selected due to the high volume of antena-
tal patients seeking MCH services and high prevalence of HIV, and for being health facilities
supported by the Elizabeth Glaser Pediatric AIDS Foundation at the time of the study approval.
Data were extracted from existing clinical charts and registers for two groups of women; the
first group attended ANC before introduction of POC technologies for CD4+ T cell enumera-
tion, hemoglobin and syphilis screening, and the second group after implementation of POC
testing.
Before introduction of POC testing, hemoglobin and syphilis testing were performed at the
laboratory associated with the health facility using Lovibond (Orbeco-Hellige, Florida, US) and
Rapid Plasma Reagin (RPR) (Biotec Lab, Suffolk, UK), respectively. Laboratories at these health
facilities possessed very basic infrastructure and equipment, were staffed by 3–4 professionals
and had relatively inefficient linkages to the corresponding referral laboratory. Nurses at the
antenatal consultation gave a test request to pregnant women, who then queued at the labora-
tory, located in a different part of the same health facility, for blood collection. Once blood was
collected, pregnant women waited for their results at the laboratory. After results were returned
to the pregnant women by laboratory staff, women went back to the antenatal consultation
where they would wait until seen by the nurse. Although the result for hemoglobin and syphilis
was available on the same day prior to this study, the inefficient flow was burdensome and
time-consuming for the client. In addition, pregnant women had to provide a separate speci-
men for CD4 counting as described below.
Blood samples for CD4+ T cell enumeration were sent weekly to the referral laboratory,
where testing was performed using the FACsCalibur (Becton Dickinson, San Jose, CA, USA).
Nurses made an appointment for blood collection for CD4 counting on a fixed day, in general
requiring therefore an extra visit. On the specimen collection day, women queued at the MCH
clinic usually at very early hours of the day. The result on the CD4 counting would only be
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available on yet a different day, requiring an additional visit to the health facility. Antiretroviral
therapy was initiated if CD4+ T-cell count was below 350cells/μL, the standard national policy
at the time of the study. Initiation was done at the ANC clinic as soon as possible after determi-
nation of eligibility.
The POC technologies introduced in January 2012 were: 1) Hemocue 201+ (Hemocue AB,
Angelholm, Sweden) for hemoglobin measurement; 2) Bioline 3.0 syphilis (Standard Diagnos-
tics Inc., South-Korea) rapid test for syphilis diagnosis; and 3) Alere PIMA (Alere Inc., Wal-
tham, Massachusetts, USA) for CD4+ T cell enumeration. All these technologies were placed
within the MCH services. At each health facility, MCH staff, laboratory staff and the medical
director of the health facility were trained on the study objectives and procedures. The change
in patient flow due to the implementation of POC technologies was discussed and arranged
with clinic staff input within the protocol training. Two nurses within each health facility were
trained to perform the tests for routine care within their MCH services. In one HF (Macia), a
clinical officer had been trained for CD4+ T-cell enumeration prior to the study and continued
supporting that service. After the training, the three POC tests were exclusively performed by
the MCH nurses at the clinic.
Procedures
Women who attended their first ANC visit between January and December 2011 for the pre-
POC evaluation, and between January and June 2012 for the post-POC evaluation, were eligible
for the study. HIV-positive women were excluded from the analysis on coverage of CD4+ T-
cell count enumeration and ART initiation if they were on ART at first ANC visit. The sample
size for HIV-positive women was calculated separately for each of the health facilities based on
a hypothesized 25% increase in ART uptake, using an 80% power and an adjustment for
incompleteness of 5%. As data on uptake of hemoglobin and syphilis testing was limited at the
time of protocol development, the study estimated to include an equal number of HIV-negative
women. For the pre-POC period, files were randomly selected for review using systematic sam-
pling. For the short post-POC evaluation, all files of the HIV-positive women were included in
order to reach the desired sample size while for HIV-negative women files were randomly
selected using systematic sampling.
Data were extracted from antenatal care cards, PMTCT register books and laboratory regis-
ter books. HIV patient files were used to cross-check laboratory results and ART initiation.
Test coverage was defined as a test result being available in either of 3 places: laboratory regis-
try, clinic registry or antenatal cards. Time from HIV diagnosis and each step of the laboratory
services up to ART initiation was measured: i) Diagnosis of HIV as written on the antenatal
cards; ii) Registration of CD4 analysis request at the MCH clinic; iii) Registration of blood col-
lection at the MCH clinic; iv) Registration of the analysis at the laboratory as written on the
CD4 result printout; v) Registration of the results at the clinic as written on the PMTCT book;
vi) Registration of results in patient file at the MCH clinic.
Structured interviews were conducted with MCH nurses and laboratory technicians to eval-
uate perceived and then actual acceptability of MCH nurses performing POC technologies,
before and after introduction, respectively. The MCH nurses and laboratory technicians were
informed about the study by the study team and interviews were conducted with those who
provided consent.
Data management and data analysis
Data were extracted onto data extraction forms and entered into a Microsoft Access database.
Data were analyzed using STATA Version SE/11.1 (Stata Corp, Texas, US). Study outcomes
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were laboratory testing and treatment uptake for syphilis for all pregnant women, testing
uptake for anemia for all pregnant women, uptake of immunological staging for HIV positive
pregnant women and uptake of ART treatment for eligible women. As the study was a retro-
spective routine data review, being screened was defined as having a test result documented in
the patient file. Eligibility for ART for the purpose of the study was defined as having a CD4
+ T cell count below 351 cells/μL. Anemia is defined as having a hemoglobin<8mg/dl. For
each health facility, we estimated the proportion with test before and after introduction of POC
technologies and compared two proportions using z-tests. In the pooled analysis, we estimated
the overall proportions before and after introduction by pooling across health facilities using
an inverse-variance weighted estimate. The overall effect of the POC was estimated by pooling
the health facility specific effects using inverse variance weights, a technique based on the ran-
dom effects model used in meta-analysis. The random effects model accounts for potential
intra-cluster (health facility) correlation in the estimation of robust standard errors.
Ethics
The protocol was approved by the National Committee for Health Bioethics of the Ministry of
Health, Mozambique and by the Ethics Committee of the George Washington University,
Washington DC, US. Signed informed consent was obtained from all health worker interview-
ees. A waiver of signed consent was obtained from the Ethics Committees for performing chart
reviews of participating pregnant women. Patient information was anonymized and de-identi-
fied prior to analysis.
Results
A total of 1673 patient files were reviewed, 865 before introduction and 808 after introduction
of the POC tests (Fig 1). Fig 1 describes the flow of patient record review. Anemia and syphilis
screening was studied in 1673 eligible records of HIV-positive and HIV-negative women, while
CD4 cell counting was investigated in files of 759 eligible HIV-positive women. Ten HIV-posi-
tive women were already on ART before the current pregnancy and excluded from the analysis
for the CD4+ T-cell enumeration and ART initiation coverage.
Characteristics of the groups are shown in Table 1. There were no differences in the age and
gestational age of women at first antenatal visit between the pre-POC and post-POC imple-
mentation periods. However, women in the post-POC implementation period had a lower
median CD4 cell count.
Table 2 describes the characteristics of health facilities. In one health facility (Moamba),
POC testing for CD4+ T-cell enumeration was available prior to this study and testing was per-
formed by a medical officer serving patients with the highest need. With the initiation of the
study, the device was moved to the MCH clinic and tests were performed by the MCH nurse,
serving MCH services.
Coverage of screening tests
Table 3 highlights the results of the coverage of screening tests, before and after introduction of
POC technologies.
Hemoglobin testing. Weighted pooled analysis showed an increase, although not signifi-
cant, in testing coverage from 67.9% (95%CI: 45.3–90.6) to 83.0% (95%CI: 74.5–91.4)
(p = 0.229). The pooled weighted difference estimate was 14.9% (95% CI: -9.4–39.2). Per health
facility (HF) analyses showed significant increases in testing coverage in two HF with initial
low coverage (Moamba and Macia) but significantly lower testing in the one HF that had high
coverage initially (Marracuene). Hemoglobin testing uptake was not significantly higher
Point-of-Care Diagnostics in Antenatal Care
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Fig 1. Consort Diagram. Flow of patient records’ review for screening of anemia, syphilis and analysis for CD4+ T-cell count and the results. Anemia is
defined as a hemoglobin <8mg/dl. Eligibility for ART is defined as having a CD4+ T-cell count <351/mg/μL. ANC, antenatal care—ART, antiretroviral therapy.
doi:10.1371/journal.pone.0135744.g001
Table 1. Characteristics of the study population (n = 1673).
Pre-POC
implementation
Post-POC
implementation
p*
Total (n, percentage) 865 808
Moamba 200 (23) 161 (20)
Macia 203 (23) 224 (28)
Magude 285 (33) 235 (29)
Marracuene 177 (21) 188 (23)
Age at first antenatal care visit (years; median (Interquartile Range)) 24 (20–29) (n = 860) 24 (20–29) (n = 807) 0.42
Gestational age at first antenatal care visit (weeks; median (Interquartile Range)) 23 (19–26) (n = 756) 22 (19–26) (n = 787) 0.05
HIV positivity (n, percentage) <0.0001
HIV negative 413 (48%) 491 (61%)
HIV positive 452 (52%) 317 (39%)
CD-4 T-cell count (HIV positive women only) (cells/μl (median, Interquartile
Range)
431 (285–622) (n = 388) 365 (230–526) (n = 255) 0.0003
Eligibility for ART, defined as CD4+ T-cell count 350 cells/μL (HIV positive
women only) (%)
35 46 0.005
* Chi-square test for comparison of categorical variables; Wilcoxon test for continuous variables
doi:10.1371/journal.pone.0135744.t001
Point-of-Care Diagnostics in Antenatal Care
PLOS ONE | DOI:10.1371/journal.pone.0135744 August 26, 2015 6 / 16
among HIV negative women compared with HIV-positive women prior to POC testing (77.2%
vs. 60.2% respectively; p = 0.47), with higher, only marginally different results after introduc-
tion of POC testing (84.1% vs. 78.9%; p = 0.06). There was no significant difference in time
from first ANC visit to hemoglobin screening between pre- (median 1 day) and post- POC
(median 1 day). Severe anemia (defined as Hb<8 mg/dl) was twice as high in HIV positive
compared with HIV negative women in the combined pre-and post-cohort (OR 1.96,
p = 0.04), but anemia treatment and clinical responses to these data were not available for
abstraction.
Syphilis testing. Coverage of syphilis screening was high initially and did not change sig-
nificantly after introduction of the POC testing (80.8% (95%CI: 65.3–96.2) vs. 87.0% (95%CI:
76.4–97.7); p = 0.282), with a pooled weighted difference of 6.0% (95% CI: -4.9–17.0). There
was no difference in testing uptake by HIV status. The effect of introduction of POC technolo-
gies on syphilis screening varied across the four health facilities. Syphilis screening rates signifi-
cantly increased in Moamba and Marracuene, were low initially and remained unchanged in
Macia, and significantly decreased in Magude. Analysis of time from first ANC visit to syphilis
screening did not show any difference, with same-day testing being performed both before and
after introduction of POC testing.
Overall rate of syphilis positivity was three times higher among HIV positive pregnant
women compared to HIV negative women (OR 0.34; p<0.0001). With the use of the non-trep-
onemal tests in the pre-POC period, syphilis positivity was 5.1% and 12.0% among HIV-nega-
tive and HIV-positive women, respectively. With the use of the more specific treponemal POC
test, positivity rates dropped to 1.5% and 5.5% among HIV-negative and HIV-positive women,
respectively. Initiation rate of syphilis treatment did not differ before [56/58 (96.6%)] and after
introduction of POC testing [19/20 (95.0%)], although with POC testing women were more
likely to be correctly identified as having syphilis.
CD4+ T cell count analyses. The weighted pooled analysis did not show a significant dif-
ference in CD4+ T cell count testing among women identified at ANC with HIV (84.9% (95%
CI: 74.7–95.2%) vs. 83.5% (95%CI: 69.0–98.0%); p = 0.930). However, health facility analyses
Table 2. Characteristics of the study health facilities.
Health Facility
(Province)
Number of
ANC
attendees
(2011)
% HIV-
positive
women in
ANC (2011)
POC Technologies
available before
study
Number of
MCH nurses
trained on
POC
Integration of
ART services at
MCH
Human Resource issues at MCH/HF
Macia (Gaza) 2744 25% Yes—CD4+ T-cell
enumeration
1 2008 2011: POC for CD4+ T-cell
enumeration operated by medical
officer at HF—used for hospitalized
patients, pediatrics, pregnant women,
referral from peripheral HF
2012: operated by MCH nurse, serving
MCH services
Moamba
(Maputo)
755 14% No 2 2013 Not reported
Magude
(Maputo)
1525 21% No 2 2013 Not reported
Marracuene
(Maputo)
1355 21% No 2 2013 1 nurse active as operator; 1 nurse
only part-time as operator.
POC CD4+ T-cell enumeration served
patients from all sectors
POC—Point-of-Care; ANC—Antenatal Care; MCH—Maternal and child health; ART—Antiretroviral therapy; HF—Health Facility
doi:10.1371/journal.pone.0135744.t002
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Table 3. Coverage of registered screening tests among the study population.
Coverage anemia screening
Pre-POC implementation Post-POC implementaton
Total N Coverage (%)– 95% CI Total N Coverage (%)– 95% CI p1
Crude 865 591 68.3 (65.2–71.4) 808 663 82.1 (79.4–84.7) <0.0001
Weighted* 865 591 67.9 (45.3–90.6) 808 663 83.0 (74.5–91.4) 0.229
Moamba 200 128 64 (57.3–70.7) 161 151 93.8 (90.0–97.5) <0.0001
Macia 203 71 35.0 (28.4–41.6) 224 173 77.2 (71.7–82.7) <0.0001
Magude 285 230 80.7 (76.1–85.3) 235 189 80.7 (76.1–85.3) 0.937
Marracuene 177 162 91.5 (87.4–95.6) 188 150 79.8 (74.0–85.5) 0.001
Coverage syphilis screening
Pre-POC implementation Post-POC implementaton
Total N Coverage (%)– 95% CI Total N Coverage (%)– 95% CI p1
Crude 865 712 82.3 (79.8–84.9) 808 691 85.5 (83.1–87.9) 0.075
Weighted* 865 712 80.8 (65.3–96.2) 808 691 87.0 (76.4–97.7) 0.282
Moamba 200 173 86.5 (81.7–91.3) 161 160 99.4 (98.2–100.6) <0.0001
Macia 203 126 62.1 (55.4–68.8) 224 140 62.5 (56.1–68.9) 0.927
Magude 285 279 97.9 (96.2–99.6) 235 220 93.6 (90.5–96.8) 0.014
Marracuene 177 134 75.7 (69.4–82.0) 188 171 91.0 (86.8–95.1) <0.0001
Coverage CD4+ T-cell count screening
Pre-POC implementation Post-POC implementaton
Total N Coverage (%) Total N Coverage (%) p1
Crude 450 388 86.2 (83.0–89.4) 309 255 82.5 (78.3–86.7) 0.164
Weighted* 450 388 84.9 (74.7–95.2) 309 255 83.5 (69.0–98.0) 0.930
Moamba 100 78 78.0 (69.8–86.2) 50 42 84.0 (73.7–94.3) 0.386
Macia 133 129 97.0 (94.0–100) 87 51 58.6 (48.2–69.0) <0.0001
Magude 139 126 90.6 (85.8–95.5) 91 82 90.1 (83.9–96.3) 0.842
Marracuene 78 55 70.5 (60.3–80.7) 81 80 98.8 (96.3–101.1) <0.0001
Time from HIV diagnosis (registered at fist ANC) to CD4+ T-cell count analysis date (registered at laboratory result) (days)
Pre-POC implementation Post-POC implementaton
N median time (d)–IQR N median time (d)—IQR p2
Total 350 9 (5–35) 245 0 (0–1) <0,0001
Moamba 64 8 (3–56) 42 0 (0–1) <0,0001
Macia 119 13 (4–35) 46 4 (0–30) 0,004
Magude 121 9 (6–35) 80 0 (0–0) <0,0001
Marracuene 46 8 (7–22) 77 0 (0–0) <0,0001
Coverage all 3 POC tests—package (HIV positive women), defined as result registered for 3 tests over HIV positive women attending 1st
antenatal care visit
Pre-POC implementation Post-POC implementaton
Total N Coverage (%)– 95% CI Total N Coverage (%)– 95% CI p1
Crude 450 206 45.7 (41.2–50.4) 309 187 60.5 (54.9–65.8) <0.0001
Weighted* 450 206 45.2 (10.7–79.6) 309 187 62.6 (25.9–99.3) 0.158
Moamba 100 65 65.0 (55.6–74.4) 50 39 78.0 (66.4–89.6) 0.104
Macia 133 13 9.8 (4.7–14.8) 87 12 13.8 (6.5–21.1) 0.358
Magude 139 103 74.1 (66.8–81.4) 91 66 72.5 (63.3–81.8) 0.792
(Continued)
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showed a significant increase in CD4+ T cell count testing in Marracuene (70.5% to 98.8%) but
a significant decrease in Macia, the facility with POC testing available prior to the study (97.0%
to 58.6%). The median time from identification of HIV at ANC to CD4+ T cell count testing
decreased significantly in the weighted pooled and stratified analysis.
Coverage of the package of 3 screening tests. More women had all three screening tests
performed when using POC testing within MCH. No significant difference was seen in the
weighted pooled analysis and stratified analysis, except for one health facility with a signifi-
cantly higher uptake (32.1% vs 86.4% before vs after introduction) in Marracuene. The very
low coverage in Macia pre-POC of 10% is explained by very low hemoglobin screening among
HIV positive women (11%). The post-POC coverage in the same facility increased but
remained low mainly due to the low CD4 T cell testing uptake.
Coverage of ART initiation
Eligibility for ART initiation based on CD4+ T cell count below 351 cells/μL was 35% in 2011
versus 46% in 2012. The cascade of HIV positive women from diagnosis to ART initiation is
shown in Fig 2. In the pre-POC period, there was a large drop-off in the number of CD4 test
results that were documented at the HF, which was not present in the post-POC period.
Initiation of ART among eligible women was similar in the weighted pooled analysis (pooled
weighted difference of -3.7% (95% CI: -54.0–46.7); p = 0.887) but significant differences were
observed in two HF (increase in Macia (40.9% to 91.3%) and decrease in Marracuene (85.7% to
22.9%)) (Table 4). The time from HIV diagnosis to ART initiation showed a trend of decrease
from a median of 50 days initially versus 16 days post-POC testing. In the HF analysis, time
decreased in all study sites and reached statistical significance in three of them (Table 4).
Acceptability
A survey was conducted among MCH nurses and laboratory technicians to assess acceptability
of performing POC at MCH. Results were similar in the pre- and post-evaluation for most
questions (Table 5). Although in the pre-evaluation participants thought that workload would
be high when using POC at MCH, this was not reported as an ongoing concern after the intro-
duction of the tests (86% before versus 21% after; p = 0.001). Most health workers preferred
POC testing to laboratory-based testing, both before and after the implementation of POC
assays in their health facilities. Although more participants were confident that more women
would be initiating ART when eligible, both in the pre-and post-evaluation, a lower percentage
felt this after introduction (77% before versus 59% after; p = 0.05).
Discussion
Our study shows that POC tests performed at MCH services within primary health care facili-
ties are potentially beneficial and well accepted by health professionals. The registration of
Table 3. (Continued)
Marracuene 78 25 32.1 (21.6–42.8) 81 70 86.4 (78.9–93.9) <0.0001
IQR Interquartile Range; POC Point-of-Care
*Pooled differences estimates (%) with 95% CI: Coverage anemia screening 14.9 (-9.4–39.2); coverage syphilis screening 6.0 (-4.9–17.0); coverage CD4
+ T-cell count -1.2 (-27.2–25.2); coverage all 3 POC tests 17.3 (-6.7–41.3)
1 z-test and logistic regression;
2 Wilcoxon rank sum test
doi:10.1371/journal.pone.0135744.t003
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diagnostics results dramatically improved with the implementation of POC diagnostics,
increasing, therefore, the likelihood of clinical action based on testing results. Additionally, the
implementation of an integrated package of three POC assays led to an overall increase of the
coverage of all three, hemoglobin, syphilis and CD4+ cells tests, among pregnant women. Nev-
ertheless, the impact on the coverage of all three assays or on the coverage of single tests was
variable, probably due to differences in conditional factors [16]. Generally speaking, the impact
was more significant in health facilities where the baseline coverage was low. Of note, in some
health facilities a significant decline in testing coverage was seen after the introduction of new
technologies. This was mainly observed in health facilities with initial high coverage of testing
and is probably due to the disruption of existing efficient work processes.
The adoption of new health technologies in health systems must be well deliberated, care-
fully planned and well monitored to avoid negative consequences on the quality of care pro-
vided by health facilities [1, 16, 17]. Task shifting of some necessary screening tests to trained
lay counselors should be evaluated. Several studies among non-pregnant women showed that
performance of CD4+ POC by non-laboratory technicians produces reliable results [2, 18].
Fig 2. Cascade HIV/ART services for HIV positive pregnant women, pre-and post-introduction of POC CD4+ T-cell count.Cascade HIV/ART services
for HIV positive pregnant women, from time of registration of HIV status to ART initiation, pre-(2010) and post-(2012) introduction of the point-of-care testing
for CD4+ T-cell enumeration performed at the maternal and child health services. All proportions are calculated with the denominator being the number of
women diagnosed with HIV. Eligibility for ART is defined as CD4+ T-cell count <351cells/μL. PW—Pregnant Women; ART—Antiretroviral Treatment.
doi:10.1371/journal.pone.0135744.g002
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Availability of multiplex instruments in which multiple tests are performed using a single fin-
ger prick may further improve work flow and increase the feasibility of conducting multiple
tests closer to patients without substantial increase in work burden [19]. The impact on service
delivery of any of these approaches would need to be monitored to ensure that there are no
unintended consequences to such changes.
The decision about the implementation of new diagnostic technologies in health systems is
based on several complex and interplaying factors [16, 20, 21]. The cost and cost-effectiveness
of the assays are critical considerations. Recent studies in resource-constrained settings have
shown that POC syphilis testing and POC CD4+ cell counting are very cost-effective [20, 22].
Another important issue is if the novel technology has an impact on patient-important out-
comes, such as morbidity, mortality or quality of life [3, 20]. Hemoglobin screening increased
significantly when test was offered at the MCH clinic. Since anemia has high disease burden for
pregnant women and their infants in resource-limited settings [6], having quantitative rapid
tests at POC can make a substantial difference in their health status. Syphilis screening has
been successfully implemented into MCH services, even before the availability of POC testing:
our data confirms coverage of about 83%, almost reaching the WHO target of 90% [21].
Although time to hemoglobin and syphilis result did not change in this study, the higher accu-
racy of POC assays we introduced is most probably associated with better diagnosis and more
appropriate clinical management. For example, after introduction of the syphilis POC trepone-
mal test the positivity rate fell from 8.1% to 2.9% due to the better specificity of the assay [23,
24], reducing thus the number of women receiving unnecessary treatment for syphilis. Surpris-
ingly, no significant increase in testing uptake was seen when syphilis diagnosis was offered at
MCH services, in contrast to the results of a study in Uganda and Zambia [25]. Results for
Table 4. Coverage of ART initiation for ART-eligible women, registered at the health facility.
Coverage ART initiation for ART-eligible women
Pre-POC implementation Pre-POC implementation
# eligible # initiated Coverage (%)– 95% CI # eligible # initiated Coverage (%) p 1
Crude 137 78 56.9 (48.5–65.0) 118 62 52.5 (43.5–61.5) 0.48
Weighted* 137 78 61.4 (42.1–80.7) 118 62 57.9 (25.0–90.9) 0.887
Moamba 22 14 63.6 (41.7–81.0) 22 16 72.7 (50.4–87.5) 0.52
Macia 44 18 40.9 (27.3–56.0) 23 21 91.3 (70.3–97.9) <0.0001
Magude 50 28 56.0 (41.9–69.2) 38 17 44.7 (29.7–60.8) 0.3
Marracuene 21 18 85.7 (11.7–39.8) 35 8 22.9 (11.7–39.8) <0.0001
Time from HIV diagnosis to ART initiation for eligibles (days)
Pre-POC implementation Pre-POC implementation
N median time (d)–IQR N median time (d)—IQR p 2
Total 78 44 (31–95) 62 17 (6–38) <0,0001
Moamba 14 62 (31–102) 16 6 (3–17) 0.0002
Macia 18 54 (33–103) 21 24 (8–40) 0.008
Magude 28 40 (24–77) 17 34 (29–69) 0.61
Marracuene 18 41 (32–65) 8 12 (7–22) 0.002
ART—Antiretroviral Therapy; POC—Point-of-Care; IQR—Interquartile Range; CI- Confidence Interval
*Pooled differences estimates with 95% CI: -3.7 (-54.0–46.7)
1z- test and logistic regression;
2Wilcoxon rank sum test
doi:10.1371/journal.pone.0135744.t004
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Table 5. Acceptability of POC tests performed at MCH by MCH nurses (n = 33) and laboratory technicians (n = 8), perceived pre-POC and actual
post-POC implementation at MCH.
Pre-POC
implementation
(n = 22)
Post-POC
implementaton
(n = 19)
P1
Age
Median (IQR) 30 (27–38) 29 (25–37)
Missing 1 1
n % n %
Sex 0.56
Male (n, %) 18 82 15 80
Missing 4 18 4 20
Do you think performing POC tests is easy? 0.25
Very easy 5 23 1 5
Easy 14 64 15 79
Difficult 2 9 0 0
No opinion 1 4 2 11
Missing 0 0 1 5
Will POC tests done at MCH services have problems? 0.27
No mistakes 19 86 14 74
Some problems might happen 3 14 5 26
Lots of problems 0 0 0 0
Will POC tests give comparable results at MCH services as with results from the laboratory? 0.65
Comparable results 19 86 14 74
Some mistakes 3 14 2 11
Missing 0 0 3 16
Will health care workers be able to attend more women with POC tests performed at MCH?2 0.59
Strongly agree 1 5 2 11
Agree 11 50 9 47
Disagree 4 18 1 5
No opinion 2 9 3 16
Missing 4 18 4 21
Will more women initiate antiretroviral treatment when POC tests done at MCH?2 0.05
Same or less 1 5 0 0
More 17 77 11 59
Maybe 0 0 1 5
No opinion 0 0 3 15
Missing 4 18 4 21
Will you have more work than before POC testing?2 0.45
Same 2 9 1 5
More work 13 59 10 53
Less work 3 14 1 5
Initially more, but later the same 0 0 0 0
No opinion 0 0 2 11
Missing 4 18 5 26
Which do you prefer?2 0.55
POC testing 17 77 15 79
Routine 1 5 0 0
No opinion 0 0 0 0
Missing 4 18 4 21
How will workload be during one single consultation? 2 0.001
Low 3 14 10 53
High 19 86 4 21
(Continued)
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CD4+ T cell count testing and ART initiation for eligible women showed variability across
study sites.
One of the most significant results of this study is that time to ART initiation decreased from
44 to 17 days with the use of POC diagnostics, reducing the probability of vertical transmission
of HIV due to a faster drop in the viral load. Additionally, the proportion of eligible women ini-
tiating ART increased significantly in those health facilities where initial coverage was low.
Interestingly, the absolute decrease in the time to ART (27 days) was higher than the one
observed for CD4+ T-cell results (9 days), indicating that other factors may be at play once
POC diagnostics are introduced. These could include more streamlined and efficient processes
within the health facilities, better predictability of test results leading to more client satisfaction
and less missed clinical appointments, and more responsiveness from health workers due to
added empowerment from POC diagnostic services [16]. In one of the facilities (Macia), where
a pre-existing POC was located outside MCH services, we saw a decrease in coverage of CD4
+ T-cell screening among HIV positive pregnant women after changing the location of the
device to within MCH services. This is probably due to a disruption of a pre-existing process
that worked efficiently. At the same time, the proportion of women starting ART increased in
this site as women were identified as eligible at the clinic, with less being lost to follow-up before
ART initiation. On the other hand, in Marracuene health facility, more women got their CD4
+ T-cell enumeration done, but less eligible women started treatment. When evaluating the pro-
cess here, we found that the MCH nurse was performing the test for non-pregnant women, tak-
ing away her time for preparing and initiating treatment of HIV positive pregnant eligible
women. In all of the four health facilities, there was no change in number of nurses after intro-
duction of POC technologies. As countries in sub-Saharan Africa implement the Option B+ for
PMTCTmore widely in the coming years, the importance of POC testing may have less impact
on the number of pregnant women that initiate ART [26]. However, immunological screening
will still be necessary for optimal clinical management and monitoring of adherence where viral
load is not available. Therefore, having POC devices at the clinic may remain essential.
To our knowledge this is the first report on the acceptability by health workers of a package
of point-of-care diagnostic services aimed at routine ANC in sub-Saharan Africa. Our results
show that POC testing was the preferred option by health professionals both before and after
the introduction of these diagnostic tools in the routine work of the health facility, and that
there was a shift in the perception of workload from high to low once the new routine was
adopted. However, with the introduction of POC diagnostics there was less optimism among
health workers regarding the impact of these technologies on the number of women initiating
ART, probably due to the realization that diagnostic delays were not the sole factor influencing
quality of care and that multiple complex factors were at play [17, 27]. The high acceptability
of POC assays may also be a reflex of the current weakness of laboratory systems throughout
sub-Saharan Africa [16] and of the empowering nature of these novel tools [16, 28].
Table 5. (Continued)
Pre-POC
implementation
(n = 22)
Post-POC
implementaton
(n = 19)
P1
Missing 0 0 5 26
POC- Point-of-Care; IQR—Interquartile Range; MCH—maternal and child health
1 Fisher Exact’s Chi square test;
2Questions asked only to MCH nurses
doi:10.1371/journal.pone.0135744.t005
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Our study had several limitations: our retrospective chart review revealed missing data. As
it was impossible to know if missing data were data not registered or tests not done, we only
considered registered information in our calculations of screening coverages. This also poten-
tially influenced the eligibility data we found in our study since we found that more women in
the post-POC implementation period had lower CD4+ T-cell counts and were ART eligible.
There has been a trend for higher CD4+ T-cell counts at ART initiation in Mozambique, with
an increase of around 10 cells/mm3 per year [29]. Nevertheless, CD4+ T-cell counts at ART ini-
tiation continue to be well below 350 cells/mm3 since patients usually present late for care [30].
There is no specific data for CD4+ T-cell count trends among pregnant women in Mozam-
bique. The difference we observed between the two periods could be caused by seasonal varia-
tions of CD4+ T-cell counts, changes in the influx of patients as a consequence to the
introduction of a new POC assay or artifacts due to missing data. We also do not know if some
women went to another HF for care, which could result in our underestimating the appropriate
follow-up and use of test results for management. Other factors such as support systems in the
HF, supervision, and monitoring can influence implementation of POC testing, and these were
not measured or accounted for in our study.
Conclusion
This study reveals that while POC tests for hemoglobin, syphilis, and CD4+ T-cell counts can
greatly improve the delivery of ANC services, having access to these technologies does not
mean that this potential is realized. There was significant variability in testing coverage before
and after implementation of POC diagnostics across the four study sites and across the three
tests performed. Multiple factors (such as site characteristics, patient volume, patient flow,
staffing) may significantly impact the implementation of POC testing services. In general,
POC testing performed at MCH is well accepted by health workers. Although there is a shift
in perceived decreased workload after its introduction, there is no perception of a potential
positive impact on initiation of ART. Further research is needed to identify optimal health
delivery strategies to effectively bring the impact of technological advances to patients that are
most at need.
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